AzTrials
AzTrials

Ankle OsteoarthritisPhase 4SUZY-TAANCT07795827

Suzetrigine for Postoperative Pain After Total Ankle Replacement

A Phase 4 study testing Suzetrigine in people with Ankle Osteoarthritis and Postoperative Pain, run by Soheil Ashkani Esfahani.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This study is testing whether adding a non-opioid pain medicine called suzetrigine (Journavx) to the usual combination of pain medicines helps people recover more comfortably after ankle replacement surgery. Adults aged 18 to 75 who are scheduled for a first-time total ankle replacement may join. Read more about this study

Who is it for?
Ages 18 to 75 years
What is being tested?
Suzetrigine
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
28 participants
Where
No sites listed yet
Study dates
1 Oct 2026to 1 Apr 2028
Phase
Phase 4
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adult patients aged 18-75 years
  • Undergoing primary total ankle arthroplasty (TAA)
  • Capable of completing study questionnaires
  • Capable of providing informed consent for enrollment
  • Capable of taking suzetrigine twice daily
  • Capable of completing the required follow-up visits

Who cannot join

  • Declines to participate or discontinues participation during the study
  • Body mass index (BMI) ≥50 kg/m²
  • Preoperative or current opioid use
  • Prior history of ipsilateral ankle infection
  • Severe hepatic impairment (Child-Pugh Class C)
  • Estimated glomerular filtration rate (eGFR) <30 mL/min
Show all 11Show fewer
  • Pregnant or lactating
  • Heart failure or recent myocardial infarction
  • Requires non-antiplatelet anticoagulant therapy (e.g., heparin, warfarin [Coumadin], apixaban [Eliquis], or enoxaparin [Lovenox])
  • Use of strong cytochrome P450 3A (CYP3A) inhibitors (e.g., itraconazole) or strong or moderate CYP3A inducers (e.g., rifampin)
  • Women taking concomitant progestin-containing contraceptives other than levonorgestrel or norethindrone who are unwilling to use an additional non-hormonal contraceptive method (e.g., condoms) or an alternative contraceptive during suzetrigine treatment and for 28 days after discontinuation

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

Mani Eftekhari, BS contact

5108506056

meftekhari@mgh.harvard.edu

About this study

Official title: Project Suzetrigine: The Efficacy and Safety of Suzetrigine (Journavx™) Following Total Ankle Arthroplasty: an Exploratory Prospective Cohort Study

This study is testing whether adding a non-opioid pain medicine called suzetrigine (Journavx) to the usual combination of pain medicines helps people recover more comfortably after ankle replacement surgery.

Adults aged 18 to 75 who are scheduled for a first-time total ankle replacement may join. Everyone who joins will receive suzetrigine in addition to their usual pain medicines. Study visits happen at the same times as normal follow-up appointments after surgery.

At these visits, participants will rate their pain, answer questionnaires about how pain affects daily life, mood, and physical activity, report how much pain medicine they have taken, report any side effects, and have their ankle motion measured.

Read the detailed description

Total ankle arthroplasty (TAA) causes substantial acute postoperative pain, typically managed with multimodal analgesia including acetaminophen, NSAIDs, and as-needed opioids. Reducing early postoperative opioid exposure is a recognized priority.

Suzetrigine is a selective NaV1.8 sodium channel inhibitor acting on peripheral pain-sensing neurons. This single-arm, open-label prospective cohort study enrolls patients undergoing primary TAA who will receive suzetrigine in addition to standard multimodal analgesia. Outcomes are compared with a historical control group of patients who underwent primary TAA at the same institution during the preceding five years and received standard multimodal analgesia alone, identified retrospectively.

Being tested
Suzetrigine
Keywords
suzetrigine, total ankle arthroplasty, postoperative pain management, foot and ankle surgery
Medical subject headings
Pain, Postoperative, Acute Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SuzetrigineDrug

    Also called Journavx

    Oral suzetrigine administered postoperatively in addition to standard multimodal analgesia.

Study groups in NCT07795827
Study groupRoleWhat they receive
GroupExperimentalParticipants undergoing primary total ankle arthroplasty receive oral suzetrigine in addition to the institution's standard multimodal analgesic regimen.
Receives: Drug: Suzetrigine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Cumulative Postoperative Opioid Consumption Through Postoperative Day 14

    Cumulative opioid consumption will be calculated as the total amount of opioid medication used from postoperative day 0 through postoperative day 14 and converted to morphine milligram equivalents (MME). Higher MME values indicate greater opioid consumption.

    Measured: Postoperative day (POD) 0 through Postoperative Day 14

Secondary outcomes (12)
  1. Pain Intensity Assessed by the Numeric Pain Rating Scale (NPRS)

    Pain intensity will be assessed using the Numeric Pain Rating Scale (NPRS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher NPRS scores indicate greater pain intensity.

    Measured: 24 hours, 2 weeks, 1 month, 3 months, and 6 months after surgery

  2. Pain Interference Assessed by PROMIS Pain Interference 6b

    Pain interference will be assessed using the Patient-Reported Outcomes Measurement Information System Short Form v1.0 - Pain Interference 6b (PROMIS Pain Interference 6b). The instrument contains 6 items assessing the extent to which pain interferes with activities and aspects of daily life. Raw scores range from 6 to 30 and are converted to standardized T-scores ranging from 41.0 to 78.3. Higher scores indicate greater pain interference and a worse outcome.

    Measured: 24 hours, 2 weeks, 1 month, 3 months, and 6 months after surgery

  3. Pain Intensity Assessed by PROMIS Pain Intensity 3a

    Pain intensity will be assessed using the Patient-Reported Outcomes Measurement Information System Scale v1.0 - Pain Intensity 3a (PROMIS Pain Intensity 3a). The instrument contains 3 items assessing worst pain, average pain, and current pain. Raw scores range from 3 to 15 and are converted to standardized T-scores ranging from 36.3 to 81.8. Higher scores indicate greater pain intensity and a worse outcome.

    Measured: 24 hours, 2 weeks, 1 month, 3 months, and 6 months after surgery

  4. Physical Function Assessed by PROMIS Physical Function 10a

    Physical function will be assessed using the Patient-Reported Outcomes Measurement Information System Short Form v2.0 - Physical Function 10a (PROMIS Physical Function 10a). The instrument contains 10 items assessing the ability to perform physical activities and activities of daily living. Raw scores range from 10 to 50 and are converted to standardized T-scores ranging from 13.5 to 61.9. Higher scores indicate better physical function and a better outcome.

    Measured: 24 hours, 2 weeks, 1 month, 3 months, and 6 months after surgery

  5. Pain Intensity Assessed by the Visual Analog Scale

    Pain intensity will be assessed using the Visual Analog Scale (VAS). Possible scores range from 0 to 10, where 0 indicates no pain and 10 indicates the worst pain imaginable. Higher scores indicate greater pain intensity and a worse outcome.

    Measured: 24 hours, 2 weeks, 1 month, 3 months, and 6 months after surgery

  6. Patient Satisfaction With Postoperative Pain Management

    Patient satisfaction with postoperative pain management will be assessed using a 6-point Likert scale. Possible scores range from 0 to 5, with higher scores indicating greater satisfaction and a better outcome. Participants will also be asked an open-ended question regarding their experience with suzetrigine; the open-ended response is qualitative and is not included in the numerical satisfaction score.

    Measured: 24 hours, 2 weeks, 1 month, 3 months, and 6 months after surgery

  7. Number of Participants With Adverse Events

    The number and proportion of participants experiencing one or more adverse events will be recorded. Patient-reported adverse events will be collected using selected items from the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), and clinician-reported adverse events will be evaluated using the Common Terminology Criteria for Adverse Events (CTCAE).

    Measured: 2 weeks, 1 month, 3 months, 6 months after surgery

  8. Severity of Adverse Events

    Severity of clinician-reported adverse events will be assessed according to the Common Terminology Criteria for Adverse Events (CTCAE), and patient-reported symptomatic adverse events will be assessed using selected items from the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Higher grades or response levels indicate greater adverse-event severity and a worse outcome. PRO-CTCAE consists of individual symptom items and does not produce a single overall composite score.

    Measured: 2 weeks, 1 month, 3 months, 6 months after surgery

  9. Proportion of Participants Opioid-Free by Postoperative Day 14

    The proportion of participants who are opioid-free by postoperative day 14 will be determined from recorded postoperative opioid use. Results will be reported as the percentage of participants who are opioid-free at postoperative day 14.

    Measured: Postoperative day 14

  10. Proportion of Participants Requiring Rescue Analgesia

    The proportion of participants requiring at least one rescue analgesic because of inadequate pain control will be recorded. Rescue analgesics include medications administered as needed when routine postoperative pain management is insufficient. A higher proportion indicates greater need for additional analgesia.

    Measured: Postoperative day 0 through postoperative day 14

  11. Baseline Risk for Opioid Use Disorder Assessed by the Opioid Risk Tool for Opioid Use Disorder

    Baseline risk for opioid use disorder will be assessed using the Opioid Risk Tool for Opioid Use Disorder (ORT-OUD), a 9-item self-report screening instrument. Total scores range from a minimum of 0 to a maximum of 9. Scores of 0-2 indicate lower risk and scores of 3-9 indicate higher risk for future opioid use disorder. Higher scores indicate greater risk and therefore a worse outcome.

    Measured: Preoperative baseline

  12. Opioid Misuse Behaviors Assessed by the Current Opioid Misuse Measure

    Postoperative opioid misuse behaviors will be assessed using the Current Opioid Misuse Measure (COMM), a 17-item self-report instrument. Each item is scored from 0 to 4, producing a total score ranging from a minimum of 0 to a maximum of 68. Higher scores indicate greater evidence of current opioid misuse behaviors and a worse outcome.

    Measured: Routine postoperative follow-up visits through 6 months after surgery at 2 weeks, 1 month, 3 months, 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 Aug 2026
  2. Study start1 Oct 2026 (estimated)
  3. Primary completion1 Oct 2027 (estimated)
  4. Study completion1 Apr 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
28 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07795827
Sponsor's protocol ID
2026P000137
Acronym
SUZY-TAA
Status last verified
Sep 2026
First submitted
25 Aug 2026
Last updated
30 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No: Individual participant data will not be shared outside Mass General Brigham because the approved protocol limits data access to IRB-approved study staff and does not authorize external sharing.

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Suzetrigine in people with Ankle Osteoarthritis and Postoperative Pain, run by Soheil Ashkani Esfahani.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 30 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Mani Eftekhari, BS (5108506056, meftekhari@mgh.harvard.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Cumulative Postoperative Opioid Consumption Through Postoperative Day 14 (time frame: Postoperative day (POD) 0 through Postoperative Day 14). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in